Order Article Reprints

Ceccanti M, Blum K, Bowirrat A, Dennen CA, Braverman ER, Baron D, Mclaughlin T, Giordano J, Gupta A, Downs BW, et al. Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. Journal of Personalized Medicine. 2022; 12(12):2015. https://doi.org/10.3390/jpm12122015

Ceccanti, Mauro, Kenneth Blum, Abdalla Bowirrat, Catherine A. Dennen, Eric R. Braverman, David Baron, Thomas Mclaughlin, John Giordano, Ashim Gupta, Bernard W. Downs, and et al. 2022. "Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids" Journal of Personalized Medicine 12, no. 12: 2015. https://doi.org/10.3390/jpm12122015

Ceccanti, M., Blum, K., Bowirrat, A., Dennen, C. A., Braverman, E. R., Baron, D., Mclaughlin, T., Giordano, J., Gupta, A., Downs, B. W., Bagchi, D., Barh, D., Elman, I., Thanos, P. K., Badgaiyan, R. D., Edwards, D., & Gold, M. S. (2022). Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. Journal of Personalized Medicine, 12(12), 2015. https://doi.org/10.3390/jpm12122015